243 related articles for article (PubMed ID: 24168056)
1. Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways.
Dong S; Kong J; Kong F; Kong J; Gao J; Ke S; Wang S; Ding X; Sun W; Zheng L
J Transl Med; 2013 Oct; 11():273. PubMed ID: 24168056
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
[TBL] [Abstract][Full Text] [Related]
3. Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins.
Zhang N; Li H; Qin C; Ma D; Zhao Y; Zhu W; Wang L
J Cancer Res Clin Oncol; 2019 Apr; 145(4):895-907. PubMed ID: 30820716
[TBL] [Abstract][Full Text] [Related]
4. LncRNA FUNDC2P4 down-regulation promotes epithelial-mesenchymal transition by reducing E-cadherin expression in residual hepatocellular carcinoma after insufficient radiofrequency ablation.
Zeng J; Cai X; Hao X; Huang F; He Z; Sun H; Lu Y; Lei J; Zeng W; Liu Y; Luo R
Int J Hyperthermia; 2018 Sep; 34(6):802-811. PubMed ID: 29295626
[TBL] [Abstract][Full Text] [Related]
5. After insufficient radiofrequency ablation, tumor-associated endothelial cells exhibit enhanced angiogenesis and promote invasiveness of residual hepatocellular carcinoma.
Kong J; Kong L; Kong J; Ke S; Gao J; Ding X; Zheng L; Sun H; Sun W
J Transl Med; 2012 Nov; 10():230. PubMed ID: 23171368
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2.
Dong S; Li Z; Kong J; Wu S; Gao J; Sun W
Int J Hyperthermia; 2022; 39(1):888-896. PubMed ID: 35848416
[TBL] [Abstract][Full Text] [Related]
7. Platelet lysates in Hepatocellular Carcinoma patients after radiofrequency ablation facilitate tumor proliferation, invasion and vasculogenic mimicry.
Jia G; Kong J; Yao C; Wu S; Sun W
Int J Med Sci; 2020; 17(14):2104-2112. PubMed ID: 32922171
[No Abstract] [Full Text] [Related]
8. Metformin exhibits the anti-proliferation and anti-invasion effects in hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Zhang Q; Kong J; Dong S; Xu W; Sun W
Cancer Cell Int; 2017; 17():48. PubMed ID: 28450808
[TBL] [Abstract][Full Text] [Related]
9.
Li Z; Jiang M; Zhang T; Liu S
Cancer Biother Radiopharm; 2021 Dec; 36(10):879-887. PubMed ID: 32799553
[No Abstract] [Full Text] [Related]
10. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling.
Zhang N; Wang L; Chai ZT; Zhu ZM; Zhu XD; Ma DN; Zhang QB; Zhao YM; Wang M; Ao JY; Ren ZG; Gao DM; Sun HC; Tang ZY
PLoS One; 2014; 9(12):e115949. PubMed ID: 25542041
[TBL] [Abstract][Full Text] [Related]
11. ATPase Inhibitory Factor 1 Promotes Hepatocellular Carcinoma Progression After Insufficient Radiofrequency Ablation, and Attenuates Cell Sensitivity to Sorafenib Therapy.
Kong J; Yao C; Ding X; Dong S; Wu S; Sun W; Zheng L
Front Oncol; 2020; 10():1080. PubMed ID: 32670888
[TBL] [Abstract][Full Text] [Related]
12. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma.
Yoshida S; Kornek M; Ikenaga N; Schmelzle M; Masuzaki R; Csizmadia E; Wu Y; Robson SC; Schuppan D
Hepatology; 2013 Nov; 58(5):1667-80. PubMed ID: 23729316
[TBL] [Abstract][Full Text] [Related]
13. β-Arrestin1 is involved in hepatocellular carcinoma metastasis via extracellular signal-regulated kinase-mediated epithelial-mesenchymal transition.
Xu X; Lei Y; Zhou H; Guo Y; Liu H; Jiang J; Yang Y; Wu B
J Gastroenterol Hepatol; 2020 Dec; 35(12):2229-2240. PubMed ID: 32445259
[TBL] [Abstract][Full Text] [Related]
14. HMGB1 released from dead tumor cells after insufficient radiofrequency ablation promotes progression of HCC residual tumor via ERK1/2 pathway.
Zhou Y; Liu X; Zhang W; Xu Y; Zhang Q; Xiong S; Tang H; Luo B
Int J Hyperthermia; 2023; 40(1):2174709. PubMed ID: 36755436
[TBL] [Abstract][Full Text] [Related]
15. Exosome-transferred long non-coding RNA ASMTL-AS1 contributes to malignant phenotypes in residual hepatocellular carcinoma after insufficient radiofrequency ablation.
Ma D; Gao X; Liu Z; Lu X; Ju H; Zhang N
Cell Prolif; 2020 Sep; 53(9):e12795. PubMed ID: 32722884
[TBL] [Abstract][Full Text] [Related]
16. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways.
Bao L; Yan Y; Xu C; Ji W; Shen S; Xu G; Zeng Y; Sun B; Qian H; Chen L; Wu M; Su C; Chen J
Cancer Lett; 2013 Sep; 337(2):226-36. PubMed ID: 23684551
[TBL] [Abstract][Full Text] [Related]
18. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells.
Zhang C; Guo F; Xu G; Ma J; Shao F
Oncol Rep; 2015 Apr; 33(4):1872-82. PubMed ID: 25653024
[TBL] [Abstract][Full Text] [Related]
19. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
20. Interferon-α Combined With Herbal Compound "Songyou Yin" Effectively Inhibits the Increased Invasiveness and Metastasis by Insufficient Radiofrequency Ablation of Hepatocellular Carcinoma in an Animal Model.
Zhang N; Wang LR; Li DD; Ma DN; Wang CH; He XG; Gao DM; Wang L; Tang ZY
Integr Cancer Ther; 2018 Dec; 17(4):1260-1269. PubMed ID: 30234394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
